Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 1
1956 1
1957 2
1958 2
1959 2
1961 1
1962 1
1963 2
1967 1
1968 1
1970 1
1973 2
1978 1
1980 3
1981 3
1982 3
1983 2
1984 1
1985 5
1986 1
1987 4
1988 3
1989 9
1990 8
1991 10
1992 10
1993 17
1994 21
1995 22
1996 35
1997 26
1998 23
1999 33
2000 35
2001 23
2002 30
2003 32
2004 24
2005 48
2006 44
2007 47
2008 51
2009 70
2010 75
2011 98
2012 107
2013 104
2014 121
2015 117
2016 136
2017 143
2018 130
2019 127
2020 137
2021 174
2022 190
2023 144
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

2,208 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Hussain M, et al. Among authors: bogemann m. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. J Clin Oncol. 2023. PMID: 36795843 Clinical Trial.
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: schlack k. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Among authors: bogemann m. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Molecular markers in bladder cancer.
Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, Shariat SF. Soria F, et al. Among authors: krabbe lm. World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26. World J Urol. 2019. PMID: 30259123 Free PMC article. Review.
The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. Schlack K, et al. Among authors: schrader aj, boegemann m, krabbe lm. Expert Rev Anticancer Ther. 2016;16(3):255-71. doi: 10.1586/14737140.2016.1143777. Epub 2016 Feb 9. Expert Rev Anticancer Ther. 2016. PMID: 26781169 Review.
Molecularly-driven precision medicine for advanced bladder cancer.
Krabbe LM, Margulis V, Schrader AJ, Shariat SF, Gust KM, Boegemann M. Krabbe LM, et al. Among authors: schrader aj, boegemann m. World J Urol. 2018 Nov;36(11):1749-1757. doi: 10.1007/s00345-018-2354-z. Epub 2018 Jun 8. World J Urol. 2018. PMID: 29948043 Review.
Therapeutic strategies for upper tract urothelial carcinoma.
Freifeld Y, Krabbe LM, Clinton TN, Woldu SL, Margulis V. Freifeld Y, et al. Among authors: krabbe lm. Expert Rev Anticancer Ther. 2018 Aug;18(8):765-774. doi: 10.1080/14737140.2018.1481395. Epub 2018 Jun 8. Expert Rev Anticancer Ther. 2018. PMID: 29848133 Review.
BRCAness in prostate cancer.
Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B. Bednarz-Knoll N, et al. Among authors: semjonow a. Oncotarget. 2019 Mar 29;10(25):2421-2422. doi: 10.18632/oncotarget.26818. eCollection 2019 Mar 29. Oncotarget. 2019. PMID: 31069005 Free PMC article. No abstract available.
2,208 results